Trajan Group Holdings Ltd (TRJ) AI Stock Analysis

• Market Cap: AU$83.13M
• Dividend Yield: N/A
• Average Volume (3M): 21.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: 7.38%
• EPS Growth: 82.39%
• Country: AU
• Employees: 600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): <0.01
• Shares Outstanding: 152,540,020
• 10 Day Avg. Volume: 15,523
• 30 Day Avg. Volume: 21,606
• PEG Ratio: 0.29
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 0.65
• P/FCF Ratio: 16.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.08
• Price Target Upside: 100.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.03
• Revenue Forecast (FY): AU$172.83M

• Rating: 47 Neutral
• Price Target: AU$0.53 ▼(-1.48% Downside)
• Action: Reiterated Date: 12/09/25
• Date: Action: Reiterated 12/09/25

Trajan Group Holdings Ltd's overall stock score is primarily impacted by its financial performance challenges, including negative net income and weak cash flow management. Technical analysis indicates a bearish trend with weak momentum. Valuation concerns arise from a negative P/E ratio and lack of dividend yield, further weighing down the score.

Positive Factors

Recurring consumables revenue

Recurring consumables sales create a high-repeat revenue base with strong customer stickiness in laboratory workflows. Over a 2–6 month horizon this durable demand improves revenue visibility, reduces customer acquisition pressure and supports steadier cash inflows versus one-time equipment sales.

Diversified end markets

Exposure across regulated testing end-markets (pharma, clinical, environmental, food) reduces single-market cyclicality and creates multiple, structurally stable demand channels. This diversification supports more resilient order pipelines and less sensitivity to a downturn in any one sector.

Modest revenue growth & healthy gross margin

Positive but modest revenue growth together with a relatively healthy gross margin indicate the core product economics are sound. Sustained gross profitability gives scope to improve operating leverage and restore overall profitability if cost controls and throughput efficiency are executed.

Negative Factors

Negative net income

Reported negative net income and a negative net profit margin weaken retained earnings and restrict the firm's ability to self-fund investments. Persistent losses impair ROE and necessitate corrective action or external capital to support strategic initiatives over coming quarters.

Declining free cash flow

A 20% fall in free cash flow and an unfavorable FCF-to-net-income profile reduce capacity to fund capex, working capital, or debt service internally. This structural cash generation weakness increases reliance on external financing and constrains strategic flexibility.

Negative ROE with moderate leverage

Moderate leverage combined with a negative ROE limits financial headroom. If operating profitability does not recover, the balance sheet could face pressure from refinancing needs or higher borrowing costs, reducing capacity to invest in growth or margin-improvement initiatives.

Trajan Group Holdings Ltd Business Overview & Revenue Model

Company Description

Trajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company operates through two segments, Analytical Products and Life Science Solutions. It offers analytical products, including syringes, GC consumables, septas, caps, liners, gas filters, and tubing products; pathology solutions; and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance. In addition, it offers automation workflow solutions, micro sampling devices, and data analysis services. Trajan Group Holdings Limited was incorporated in 2011 and is headquartered in Ringwood, Australia.

How the Company Makes Money

Trajan Group Holdings generates revenue through multiple key streams, primarily from the sale of its innovative laboratory and analytical products. The company profits by providing specialized consumables and equipment to laboratories, research institutions, and healthcare providers. Additionally, Trajan engages in partnerships and collaborations with other organizations in the healthcare sector, enhancing its market reach and technological capabilities. The company also focuses on recurring revenue through consumables, which are essential for ongoing laboratory operations, thereby establishing a stable income base. Furthermore, Trajan may benefit from strategic acquisitions that expand its product offerings and market presence.

Trajan Group Holdings Ltd Financial Statement Overview

Summary

Trajan Group Holdings Ltd is experiencing moderate revenue growth but faces profitability challenges with negative net income. The balance sheet shows a stable equity position but is impacted by the negative return on equity. Cash flow management needs improvement, particularly in generating free cash flow.

Income Statement

Trajan Group Holdings Ltd has shown a modest revenue growth rate of 4.29% in the most recent year, indicating a positive trend. However, the company is currently experiencing negative net income, resulting in a negative net profit margin. The gross profit margin is relatively healthy, but the EBIT and EBITDA margins are low, suggesting challenges in operational efficiency and cost management.

Balance Sheet

The company's debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. However, the return on equity is negative due to the net loss, which is a concern. The equity ratio is stable, showing a solid foundation of equity relative to total assets.

Cash Flow

Free cash flow has decreased by 20.04%, which is a negative indicator. The operating cash flow is positive and covers net income, but the free cash flow to net income ratio is not favorable due to the net loss. The company needs to improve its cash flow generation to support operations and growth.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	169.52M	166.46M	155.02M	162.15M	107.57M	76.57M
Gross Profit	42.31M	63.47M	59.75M	22.93M	42.63M	28.48M
EBITDA	6.69M	8.14M	-20.36M	14.16M	5.14M	3.46M
Net Income	-1.38M	-4.46M	-25.33M	1.89M	1.70M	1.88M
Balance Sheet
Total Assets	192.32M	195.63M	188.00M	229.04M	206.78M	99.38M
Cash, Cash Equivalents and Short-Term Investments	12.78M	11.85M	11.24M	11.04M	13.16M	51.72M
Total Debt	69.37M	55.49M	56.16M	61.30M	66.18M	17.02M
Total Liabilities	89.27M	90.01M	85.15M	99.51M	90.27M	33.30M
Stockholders Equity	103.05M	105.62M	102.85M	129.53M	116.51M	66.08M
Cash Flow
Free Cash Flow	1.46M	6.74M	6.43M	998.00K	-1.28M	8.34M
Operating Cash Flow	4.47M	10.83M	9.47M	9.55M	2.13M	9.45M
Investing Cash Flow	-3.02M	-4.09M	-3.04M	-8.55M	-116.38M	402.00K
Financing Cash Flow	1.57M	-5.64M	-6.40M	-3.36M	74.69M	36.81M

Trajan Group Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.66, and below the 200-day MA of 0.75, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 21.01 is Positive, neither overbought nor oversold. The STOCH value of 27.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRJ.

Trajan Group Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AHC	63 Neutral	AU$133.04M	16.82	12.35%	―	39.98%	-30.04%
EZZ	60 Neutral	AU$59.51M	25.12	27.24%	2.81%	0.65%	-9.90%
ALA	52 Neutral	AU$95.37M	-11.29	-47.98%	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRJ	47 Neutral	AU$83.13M	-60.56	-4.28%	―	7.38%	82.39%
CYC	44 Neutral	AU$98.30M	-5.21	-31.98%	―	34.20%	-23.90%
SHG	43 Neutral	AU$78.92M	-10.25	―	―	―	―

Trajan Group Holdings Ltd Corporate Events

Trajan Narrowly Reduces Half-Year Loss Despite Modest Revenue Growth

Trajan Group Holdings Limited reported a 3.8% increase in revenue to $84.1 million for the half-year ended 31 December 2025, but recorded a net loss after tax attributable to shareholders of $0.4 million, an 87.5% improvement in the loss position compared with the prior corresponding period. Comprehensive profit attributable to owners swung to a loss of $2.7 million, indicating ongoing earnings volatility despite modest top-line growth.

The company maintained a cautious capital stance, with no dividend declared or proposed for the half-year, underscoring a focus on reinvestment or balance sheet resilience. Net tangible assets per share improved slightly to $0.09 from $0.08, while the group’s structure remained stable, with no acquisitions, disposals, associates or joint ventures added or lost during the period, and its interim financial statements subjected to an auditor review.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Holds FY26 Guidance as Q2 Rebound Offsets Soft Start

Trajan Group Holdings has reaffirmed its full-year FY26 guidance despite a softer first quarter that weighed on half-year earnings, reporting expected group net revenue growth of 3.8% to $84.1 million for the first half and a decline in normalised EBITDA to $5.0 million, impacted by FX-related asset revaluations, higher freight and timing effects from US tariff recoveries. Management highlighted a sharp improvement in the second quarter, with record quarterly revenue of $45.4 million, a $2.8 million uplift in the capital equipment order book to $10.8 million, and Q2 nEBITDA of $4.5 million, and said recent cost-cutting under Project Neptune and January price increases should support margin expansion and underpin guidance for FY26 net revenue above $170 million and nEBITDA above $16 million, as the resilient components and consumables business offsets volatility in capital equipment.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Sets Date for FY26 Half-Year Results and Investor Webcast

Trajan Group Holdings Limited has announced that it will release its financial results for the first half of the 2026 financial year, covering the period ending 30 June 2026, on 26 February 2026. The company will host a live investor webcast and Q&A on the same day, led by CEO and Managing Director Stephen Tomisich and Chief Financial Officer Alister Hodges, with investors able to register in advance and submit questions, underscoring Trajan’s ongoing engagement with the market and its stakeholders ahead of the detailed financial update.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.